Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for at least one year~* HbA1c 7-11% (both inclusive)~* Treated with insulin for at least six months - any regimen~Exclusion Criteria:~* Any systemic treatment with products which in the Investigator's opinion could interfere with glucose or lipid metabolism (eg systemic corticosteroids) 3 months prior to randomisation~* Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SIBA (D) (Type: EXPERIMENTAL): None
- SIBA (E) (Type: EXPERIMENTAL): None
- IGlar (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).